Procalcitonin decrease over 72 hours in US critical care units predicts fatal outcome in sepsis patients by Schuetz, Philipp et al.
 
Procalcitonin decrease over 72 hours in US critical care units
predicts fatal outcome in sepsis patients
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Schuetz, Philipp, Paula Maurer, Vikas Punjabi, Ami Desai,
Devendra N Amin, and Eric Gluck. 2013. “Procalcitonin
decrease over 72 hours in US critical care units predicts fatal
outcome in sepsis patients.” Critical Care 17 (3): R115.
doi:10.1186/cc12787. http://dx.doi.org/10.1186/cc12787.
Published Version doi:10.1186/cc12787
Accessed February 16, 2015 10:40:54 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406608
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAARESEARCH Open Access
Procalcitonin decrease over 72 hours in US
critical care units predicts fatal outcome
in sepsis patients
Philipp Schuetz
1*, Paula Maurer
2, Vikas Punjabi
3, Ami Desai
3, Devendra N Amin
2† and Eric Gluck
3†
Abstract
Introduction: Close monitoring and repeated risk assessment of sepsis patients in the intensive care unit (ICU) is
important for decisions regarding care intensification or early discharge to the ward. We studied whether
considering plasma kinetics of procalcitonin, a biomarker of systemic bacterial infection, over the first 72 critical
care hours improved mortality prognostication of septic patients from two US settings.
Methods: This retrospective analysis included consecutively treated eligible adults with a diagnosis of sepsis from
critical care units in two independent institutions in Clearwater, FL and Chicago, IL. Cohorts were used for
derivation or validation to study the association between procalcitonin change over the first 72 critical care hours
and mortality.
Results: ICU/in-hospital mortality rates were 29.2%/31.8% in the derivation cohort (n = 154) and 17.6%/29.4% in
the validation cohort (n = 102). In logistic regression analysis of both cohorts, procalcitonin change was strongly
associated with ICU and in-hospital mortality independent of clinical risk scores (Acute Physiology, Age and
Chronic Health Evaluation IV or Simplified Acute Physiology Score II), with area under the curve (AUC) from 0.67 to
0.71. When procalcitonin decreased by at least 80%, the negative predictive value for ICU/in-hospital mortality was
90%/90% in the derivation cohort, and 91%/79% in the validation cohort. When procalcitonin showed no decrease
or increased, the respective positive predictive values were 48%/48% and 36%/52%.
Discussion: In septic patients, procalcitonin kinetics over the first 72 critical care hours provide prognostic information
beyond that available from clinical risk scores. If these observations are confirmed, procalcitonin monitoring may assist
physician decision-making regarding care intensification or early transfer from the ICU to the floor.
Keywords: Sepsis, Severe sepsis, Septic shock, Biomarker, Procalcitonin, Procalcitonin kinetics, Procalcitonin change,
Mortality, Mortality prediction, APACHE IV, SAPS II, Clinical risk score
Introduction
Accurately assessing risk of poor outcome in intensive
care unit (ICU) and other critical care patients with sepsis
is challenging, but may help improve patient management
and decrease sepsis-related morbidity and mortality. Since
prompt and specific treatment in those with severe sepsis
and septic shock has been shown to improve outcomes
[1], it is vital to ensure a timely diagnosis of this disease
process. Once stabilized in the critical care setting, sepsis
patients may be transferred to a medical ward for further
treatment. In clinical practice, appropriate transfer deci-
sions are important, as treatment failure on the floor
leading to ICU readmission is associated with adverse
prognosis and prolonged stays [2]. However, such deci-
sions are challenging, because the clinical presentation
may not always reflect readiness for discharge. Therefore,
applying an accurate risk stratification tool after prompt
diagnosis and treatment of sepsis in critical care units
would allow identification ofp a t i e n t sa tl o wr i s kf o r
adverse outcome who are ready for ICU discharge and, at
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cation of therapy.
One candidate risk stratification tool is procalcitonin
(PCT), the 116-amino acid prohormone of the calcium
metabolism regulator, calcitonin [3]. PCT is a biomarker
of systemic bacterial infection and sepsis, because although
mature calcitonin is exclusively produced by thyroid gland
C-cells, PCT is synthesized in numerous extra-thyroidal
tissues in response to lipopolysaccharides and bacterially-
induced cytokines [4]. Plasma PCT levels rise within
approximately three to six hours of initial clinical manifes-
tation of sepsis and fall if the sepsis is controlled.
Previous research, mainly from Europe, showed that
changes over time in biomarkers including PCT and C-
reactive protein (CRP) may be used to monitor patients
with sepsis, respiratory infections or both in the ICU
[5-11]. These studies have suggested that a decrease in
PCT concentration may help guide physicians on when to
de-escalate antibiotic therapy in medical as well as surgical
ICU patients [6-11]. European studies also showed that
PCT kinetics have prognostic implications, as falling
values correlate with good outcomes, while static or
increasing values correlate with adverse outcomes includ-
ing mortality [12-14]. However, there are as yet no
accepted cut-offs for risk assessment in ICU patients, and
reports from US settings are largely lacking.
We therefore retrospectively analyzed data from
patients in critical care units with a diagnosis of sepsis
(confirmed or probable) from two independent US health
care institutions to investigate the prognostic information
obtainable from the change in PCT concentration from
the admission PCT level and a repeated PCT measure-
ment 72 critical care hours later. The analysis sought to
derive and preliminarily validate cut-off levels for mortal-
ity risk stratification that could be further validated in
prospective trials.
Materials and methods
Study design, patients and setting
This observational study included two independent
c o h o r t so fa d u l t sc o n s e c u t i v e ly admitted to critical care
units for the main diagnosis of sepsis based on Interna-
tional Classification of Diseases edition 9 coding and med-
ical record review. Upfront, we designated as a derivation
cohort the larger group, patients treated at an 18-bed
adult medical-surgical ICU, at Morton Plant Hospital,
Clearwater, Florida, a 687-bed community referral center,
between January 2009 and April 2010. All patients in this
cohort fulfilled the criteria of either severe sepsis (18%) or
septic shock (82%) as prospectively routinely assessed in
the institutional sepsis surveillance protocol. We assigned
as a validation cohort the patients hospitalized in a 14-bed
adult medical-surgical ICU or a 16-bed adult intermediate
care unit at the Swedish Covenant Hospital, Chicago,
Illinois, a 350-bed inner-city tertiary referral center,
between January 2009 and March 2011. All patients in the
Swedish Covenant cohort had a systemic bacterial infec-
tion as a main diagnosis and were considered by the treat-
ing physicians to have sepsis. However, due to our
retrospective study design, it was not possible to confirm
that each fulfilled criteria for severe sepsis or septic shock.
To be eligible for either cohort, patients needed to have
one PCT measurement upon admission (within 24 hours)
and one draw 72 (± 12) hours thereafter during an unin-
terrupted critical care stay. Retrospective collection and
analysis of data from each cohort was approved before-
hand by the respective local institutional review board
(IRB) (that is, Pasco-Pinellas IRB of Morton Plant Mease
Health Care, Florida and the Swedish Covenant IRB, Chi-
cago, IL). Both IRBs granted a waiver for informed consent
since the study was anonymous and, because of its retro-
spective nature, entailed no patient interventions.
Data collection
For the derivation cohort, data were extracted using ICU
Tracker
® (Alere Informatics Solutions, Charlottesville, VA,
USA), an electronic acquisition database drawing from
electronic feeds of demographic, clinical, vital signs,
laboratory, co-morbidity, complication, pharmacy and bill-
ing information. ICU and hospital length-of-stay (LOS),
A c u t eP h y s i o l o g y ,A g ea n dC h r o n i cH e a l t hE v a l u a t i o n
(APACHE) IV score at ICU admission and observed mor-
tality rates also were obtained through ICU Tracker
®.
Additional data were acquired using Theradoc
® (Hospira,
Lake Forest, IL, USA), an electronic infection control sur-
veillance product. Further, ICU charts were manually
reviewed for data verification in case of uncertainty.
Similarly, for the validation cohort, we extracted data
from all patients’ electronic medical records of their
hospital stays. In particular, we gathered and used for
the analysis: (a) patient identification number; (b) socio-
demographic characteristics; (c) laboratory results
including all PCT measurements; (d) Simplified Acute
Physiology Score (SAPS) II at critical care unit admis-
sion; (e) co-morbidities based on Diagnosis-Related
Group codings; (f) sepsis-specific medication(s); (g) ICU
and hospital LOS; and (h) vital status during the ICU
and hospital stay.
PCT measurement
For PCT measurement, the Clearwater institution used the
VIDAS B.R.A.H.M.S PCT assay (bioMérieux, Marcy
L’Etoile, France), an automated heterogeneous sandwich
immunoassay with fluorescence detection. Total assay
time of the VIDAS method is 20 minutes with a measur-
ing range of 0.05 to 200 μg/L and a functional sensitivity
of 0.09 μg/L. The Chicago institution used a time-resolved
amplified cryptate emission technology assay (B·R·A·H·M·S
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®, Thermo Scientific Biomarkers,
Hennigsdorf, Germany) with a 0.019 µg/L lower limit of
detection, a 0.06 μg/L functional sensitivity, and ≤3%
intra-assay or inter-assay coefficients of variation [15].
Both methods have shown an excellent correlation and
concordance and both can be used with the same nominal
PCT cut-off ranges in clinical routine [16]. The initial
PCT result in all patients was on the day of ICU admis-
sion. In patients in whom more than one follow-up PCT
measurement was available for the period 72 ± 12 hours
after the initial value, the one closest to 72 hours was used
for the study analyses.
Hypothesis and statistics
We hypothesized that the magnitude of the relative
change in PCT concentration within 24 hours of ICU
admission until after 72 ± 12 hours in the critical care
setting would be associated with all-cause ICU and in-
hospital mortality, our primary endpoints. As previously
suggested [17], to test this hypothesis, we performed
logistic regression analyses and calculated odds ratios
(ORs) and their 95% confidence intervals (CIs). To
improve the model fit, we transformed relative PCT
change into deciles before modeling. In a separate analy-
sis, we also adjusted the models for illness severity using
the initial severity of illness score that was routinely cal-
culated in each institution. Specifically, the APACHE IV
was used in the derivation cohort and SAPS II in the
validation cohort. We assessed the discrimination pro-
v i d e db y7 2 - h o u rP C Tc h a n g ea sam o r t a l i t yp r e d i c t o r
by calculating the area under the receiver operating
characteristic curve (AUC of the ROC curve), which
reflects the probability that a tested predictive variable/
method will correctly categorize an individual. The AUC
is derived by plotting the sensitivity (true-positive rate)
against 1-the specificity (false-positive rate) associated
with given values of the predictive variable/method. An
AUC of 0.5 implies that the tested variable/method is no
more accurate than a coin toss, whereas an AUC of 1.0
means that the variable/method is always correct; values
around 0.7 or greater are generally deemed to suggest
that the tested variable/method may have clinical utility.
Calibration of the regression models was assessed with
Hosmer-Lemeshow Goodness of Fit tests. Additionally,
we examined whether combining the PCT change with
clinical risk scores, namely APACHE IV (derivation
cohort) or SAPS II (validation cohort), at ICU admission,
improved mortality prediction accuracy over that
attained with the respective score alone. To do so, we
compared AUCs of a logistic regression model of the
clinical score by itself versus the AUCs of a model com-
bining the clinical score plus the PCT change. We also
dichotomized the 72-hour PCT change at four different
cut-off levels, namely: (1) 0% decrease or PCT increase;
(2) 40% decrease; (3) 60% decrease; and (4) 80% or more
decrease. For these cut-offs, we calculated sensitivity, spe-
cificity, and positive and negative predictive values.
All statistical analyses were done with SAS 6.12 (SAS
Institute, Cary, NC, USA) or STATA 9.2 (Stata Corp.,
College Station, TX, USA). Mean values are reported
with their standard deviation (SD), and median values
with their interquartile range (IQR, 25
th to 75
th percen-
tile). All testing was two-tailed and P-values under 0.05
were considered statistically significant.
Results
Study cohort characteristics
Characteristics of the two patient populations are pre-
sented in Table 1. The derivation and validation cohorts
had virtually the same mean age. However, there was a
trend towards a statistically significant difference between
the groups in gender composition and there were statisti-
cally significant differences in racial composition and in
distribution of the primary locus for sepsis. Specifically,
the derivation cohort was more female and much more
Caucasian than was the validation cohort. Additionally,
the derivation cohort far more often had the urinary tract
and the validation cohort far more often had other sites as
the primary locus for sepsis. In both groups, however, the
respiratory tract and abdomen were the two commonest
primary loci for sepsis, and primary bacteremia with
uncertain clinical focus had very similar prevalence.
Mean PCT levels on admission were 17.9% higher in the
derivation cohort and, on a relative basis, fell substantially
more sharply over the studied interval in that group com-
pared to the validation cohort (61.9% versus 40.9% mean
relative decrease). Hospital LOS was comparable between
the cohorts, as was in-hospital mortality. However, critical
care unit LOS was slightly but significantly longer and
ICU mortality was appreciably and significantly higher in
the derivation cohort.
Derivation cohort
In the derivation cohort, the mean (SD) relative individual
change in PCT concentration from admission to 72 hours
was -46% (± 39%) and the median (IQR) individual change
was -66% (-38% to -81%). PCT kinetics over 72 hours were
strongly associated with ICU and in-hospital mortality
(adjusted OR [95%CI] per 10% PCT increase 1.3 [1.1 to
1.5], P = 0.001 and 1.3 [1.1 to 1.4], P = 0.001, respectively)
(Table 2). The association of the 72-hour PCT change with
outcomes (ICU mortality and in-hospital mortality) was
assessed using logistic regression analysis. Goodness of Fit
testing showed no evidence of miscalibration (P =0 . 9 5a n d
P = 0.93). The 72-hour PCT change or the APACHE IV
score at ICU admission provided similar discrimination of
ICU survivors versus non-survivors (AUC 0.70 versus 0.66)
and hospital survivors versus non-survivors (AUC 0.70
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score in a joint logistic model tended to improve discrimi-
nation relative to use of the risk score alone (AUC 0.73,
P = 0.01 for ICU mortality and AUC 0.75, P = 0.06 for in-
hospital mortality).
Based on ROC analysis, we defined four different 72-
hour PCT change cut-offs to separate hospital survivors
from non-survivors. The mortality rates within the resul-
tant ranges are presented in Table 3. In the derivation
cohort, ICU mortality rose from 9.5% in patients with a
PCT decrease of >80% to 47.8% in patients with no
decrease or an increase. Results for in-hospital mortality
were similar. Table 4 presents sensitivities, specificities,
and negative and positive predictive values at the differ-
ent cut-offs. In the derivation cohort, a PCT decrease of
>80% had a high negative predictive value of 90% for ICU
mortality with a sensitivity of 91%, while the positive
Table 1 Characteristics of the two study cohorts
Variable Derivation cohort
(number = 154)
Validation cohort
(number = 102)
P
Demographics
Age (years), mean ± SD 65.8 ± 16.2 65.8 ±17.0 0.97
Female gender, % (number) 55.2% (85) 43.1% (44) 0.06
Race, % (number) <0.01
White 89.6%(138) 48.0% (49)
African-American 6.5% (10) 13.7% (14)
Hispanic 0 0% (0) 15.7% (16)
Asian 3.9% (6) 12.7% (13)
Other 0% (0) 9.8% (10)
Primary locus for sepsis, % (number) <0.01
Respiratory tract 45.5% (70) 39.2% (40)
Intra-abdominal 21.4% (33) 13.7% (14)
Skin 0 (0) 2.0% (2)
Urinary tract 16.9% (26) 3.9% (4)
Bacteremia without organ specified 13.0% (20) 13.7% (14)
Other infections including nervous system, prosthesis, heart, abscesses 3.3% (5) 27.5% (28)
Type of admission, % (number) 0.68
Medical 83.1% (128) 84.3% (86)
Surgical 17.6% (26) 15.7% (16)
Admission risk score, mean ± SD
APACHE IV 81.8 ± 25.9 NA
SAPS II NA 45.3 ± 14.3
PCT concentrations (µg/L), mean ± SD
Admission 32.6 ± 40.6 27.4 ± 44.9 0.34
After 72 ± 12 hours in ICU 13.3 ± 21.8 16.1 ± 40.4 0.46
Length-of-stay, days, mean ± SD
ICU 7.7 ± 6.3 6.9 ± 5.1 0.04
Total hospital 15.9 ± 10.7 15.4 ±10.1 0.66
Mortality, % (number), 95% CI
ICU 29.2% (45) 22.0% to 36.4%] 17.6% (18) 10.1% to 25.2% 0.04
Total in-hospital 31.8% (49) 24.4% to 39.3% 29.4% (30) 20.4% to 38.5%) 0.68
APACHE, Acute Physiology, Age and Chronic Health Evaluation; CI, confidence interval; ICU, intensive care unit; PCT, procalcitonin; SAPS, Simplified Acute
Physiology Score
Table 2 Association of 72-hour PCT kinetics and ICU and
total in-hospital mortality
Derivation cohort
(number = 154)
Validation cohort
(number = 102)
Discrimination: AUC (95%CI)
ICU mortality 0.70 (0.61, 0.79) 0.71 (0.57, 0.84)
In-hospital mortality 0.70 (0.61, 0.78) 0.67 (0.54, 0.79)
Adjusted regression analyses
a OR (95%CI), P value
ICU mortality
Per 10% PCT decrease 1.3 (1.1, 1.5), 0.001 1.3 (1.1, 1.6), 0.01
In-hospital mortality
Per 10% PCT decrease 1.3 (1.1, 1.4), 0.001 1.2 (1.04, 1.4), 0.012
aAdjusted for severity using the clinical risk score routinely obtained at ICU
admission (APACHE IV score in the derivation cohort, SAPS II score in the
validation cohort). AUC, area under the receiver operating characteristic curve;
CI, confidence interval; ICU, intensive care unit; OR, odds ratio; PCT,
procalcitonin.
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was 48%, with a specificity of 89%. Results for in-hospital
mortality were similar.
Validation cohort
In the validation cohort, the mean (SD) relative change in
PCT concentration from admission to 72 hours was -26%
(± 26%) and the median (IQR) change was -68% (-1% to
-83%). As in the derivation cohort, 72-hour PCT kinetics
were significantly associated with ICU and in-hospital
mortality in an adjusted logistic regression analysis
(adjusted OR [95%CI] per 10% PCT decrease, 1.3 [1.1 to
1.6], P = 0.01 and 1.2 [1.04 to 1.4], P = 0.012, respec-
tively). Discrimination provided by the PCT change was
higher than that provided by the SAPS II score for ICU
mortality (AUC 0.71 versus 0.57) and in-hospital mortal-
ity (AUC 0.67 versus 0.61). In this cohort, too, addition
of 72-hour PCT kinetics to the clinical risk score (here
Table 3 72-hour PCT kinetics and mortality
PCT kinetics over 72 ± 12 hours Derivation cohort (number = 154) Validation cohort (number = 102)
ICU mortality
PCT increase 47.8% (number = 11/23) 36.0% (number = 9/25)
PCT decrease 0% to 40% 52.9% (number = 9/17) 21.4% (number = 3/14)
PCT decrease 40% to 60% 30.4% (number = 7/23) 25.0% (number = 2/8)
PCT decrease 60% to 80% 28.6% (number = 14/49) 4.8% (number = 1/21)
PCT decrease >80% 9.5% (number = 4/42) 8.8% (number = 3/34)
In-hospital mortality
PCT increase 47.8% (number = 11/23) 52.0% (number = 13/25)
PCT decrease 0% to 40% 52.9% (number = 9/17) 42.9% (number = 6/14)
PCT decrease 40% to 60% 39.1% (number = 9/23) 25.0% (number = 2/8)
PCT decrease 60% to 80% 32.7% (number = 16/49) 9.5% (number = 2/21)
PCT decrease >80% 9.5% (number = 4/42) 20.6% (number = 7/34)
PCT, procalcitonin
Table 4 Sensitivity, specificity, positive and negative predictive values for ICU and in-hospital mortality at different
PCT kinetics cut-offs
Cut-off Sensitivity (95%CI) Specificity (95%CI) PPV
(95%CI)
NPV
(95%CI)
Part A: ICU mortality
Derivation cohort
0% PCT decrease 0.24 (0.13-0.40) 0.89 (0.82-0.94) 0.48 (0.27-0.69) 0.74 (0.66-0.81)
40% PCT decrease 0.44 (0.30-0.60) 0.82 (0.73-0.88) 0.50 (0.34-0.66) 0.78 (0.69-0.85)
60% PCT decrease 0.60 (0.44-0.74) 0.67 (0.57-0.76) 0.43 (0.30-0.56) 0.80 (0.71-0.88)
80% PCT decrease 0.91 (0.79-0.98) 0.35 (0.26-0.45) 0.37 (0.28-0.46) 0.90 (0.77-0.97)
Validation cohort
0% PCT decrease 0.50 (0.26-0.74) 0.81 (0.71-0.89) 0.36 (0.18-0.57) 0.88 (0.79-0.95)
40% PCT decrease 0.67 (0.41-0.87) 0.68 (0.57-0.78) 0.31 (0.17-0.48) 0.90 (0.80-0.96)
60% PCT decrease 0.78 (0.52-0.94) 0.61 (0.49-0.71) 0.30 (0.17-0.45) 0.93 (0.82-0.98)
80% PCT decrease 0.83 (0.59-0.96) 0.37 (0.27-0.48) 0.22 (0.13-0.34) 0.91 (0.76-0.98)
Part B: In-hospital mortality
Derivation cohort
0% PCT decrease 0.22 (0.12-0.37) 0.89 (0.81-0.94) 0.48 (0.27-0.69) 0.71 (0.62-0.79)
40% PCT decrease 0.41 (0.27-0.56) 0.81 (0.72-0.88) 0.50 (0.34-0.66) 0.75 (0.66-0.82)
60% PCT decrease 0.59 (0.44-0.73) 0.68 (0.58-0.76) 0.46 (0.33-0.59) 0.78 (0.68-0.86)
80% PCT decrease 0.92 (0.80-0.98) 0.36 (0.27-0.46) 0.40 (0.31-0.50) 0.90 (0.77-0.97)
Validation cohort
0% PCT decrease 0.43 (0.25-0.63) 0.83 (0.73-0.91) 0.52 (0.31-0.72) 0.78 (0.67-0.87)
40% PCT decrease 0.63 (0.44-0.80) 0.72 (0.60-0.82) 0.49 (0.32-0.65) 0.83 (0.71-0.91)
60% PCT decrease 0.70 (0.51-0.85) 0.64 (0.52-0.75) 0.45 (0.30-0.60) 0.84 (0.71-0.92)
80% PCT decrease 0.77 (0.58-0.90) 0.38 (0.26-0.50) 0.34 (0.23-0.46) 0.79 (0.62-0.91)
CI, confidence interval; NPV, negative predictive value; PCT, procalcitonin; PPV, positive predictive value
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increased the prognostic accuracy (AUC 0.70 and 0.68)
relative to that attained with the risk score alone. Again,
there was no evidence of miscalibration in Goodness of
Fit statistics for either outcome (P = 0.51 and P = 0.19).
Diagnostic performance of the different cut-offs was
comparable to that in the derivation cohort (Table 4).
Yet, the 80% PCT decrease cut-off had appreciably
lower sensitivity and negative predictive value regarding
in-hospital mortality (79% and 77%) than it did in the
derivation set, but almost identical specificity,. When
PCT did not decrease or increased, the positive predic-
tive value was high (52%) with high specificity (83%),
similar to this criterion’s performance in the derivation
cohort.
Discussion
This retrospective analysis of data from two independent
US critical care settings found 72-hour PCT kinetics to
be an accurate mortality predictor in intensively treated
patients with sepsis. This finding was independent of
initial severity assessment as reflected by the widely used
APACHE IV or SAPS II clinical risk scores and validates
similar results from Europe in patients with sepsis and
severe systemic infections such as pneumonia [13-15].
Our data suggest that monitoring PCT kinetics in the
first 72 hours of critical care provides information that
may potentially help improve early transfer and therapy
intensification decisions. Particularly, a PCT decrease
>80% may help to identify individuals at reduced mortal-
ity risk who, therefore, are good early ICU discharge can-
didates. Conversely, a non-decrease or increase of PCT
within this timeframe may help to flag patients who are
at high mortality risk and, therefore, are likely to require
treatment escalation.
Accurate disease severity assessment and clinical
course prediction assist patients, families, and caregivers
in setting realistic expectations regarding the illness.
Accurate stratification and prognostication are also
prerequisites for appropriately applying health care
resources and therapeutic options. Informative commu-
nication with patients and significant others and effective
patient management decision-making are particularly
important in the care of severe stages of sepsis, which
have a high morbidity and mortality risk. The value of
prognostication is acknowledged by guidelines, which
recommend stratifying patients with sepsis based on pre-
dicted mortality according to validated clinical risk
scores, that is, SAPS or APACHE [18,19]. However, clini-
cal risk scores are somewhat limited by practicality issues
and are only validated when admission values are used;
indeed, the utility of monitoring these scores over the
course of sepsis is not well-established. The scores also
may suffer from miscalibration, and, therefore, have only
moderate operational characteristics, due to differences
between the patient populations in whom the scores
were developed and applied. Thus, there is interest in
predictive use of newly available biomarkers that are
objectively and rapidly measurable, respond to clinical
recovery and add relevant, reliable, real-time information
[20].
Although different clinical studies have produced
results favoring PCT as a monitoring marker in sepsis
and respiratory infections [13-15], there is currently a
lack of widely-accepted cut-offs, that is, actionable bio-
marker levels, which would allow meaningful integration
of PCT kinetics into patient prognostication in critical
care. However, numerous randomized controlled trials
have successfully employed PCT cut-offs for antibiotic
stewardship in the medical and surgical ICU settings,
mainly in patients with underlying respiratory infections,
markedly decreasing antibiotic consumption without
increasing mortality or treatment failure [11,14,21-23].
A smaller number of studies (reviewed in [14]) have
evaluated the prognostic potential of PCT in sepsis, mainly
looking at European patients. A Finnish investigation
found PCT concentrations to be higher in more severe
cases of advanced sepsis, but a substantial decrease in con-
centration was a more important survival predictor than
were absolute values [13]. A 472-patient Danish study
found a high maximum PCT level or a PCT increase for
more than one day to be early independent predictors of
90-day all-cause mortality in ICU patients with sepsis [24];
these authors also observed that mortality risk rose with
the number of days that PCT increased. Yet a large inter-
ventional trial testing the survival impact of therapy escala-
tion in sepsis patients in whom PCT did not decrease
appropriately could not show a benefit for PCT-guided
escalation [12]; in fact, due to prolonged antibiotic therapy,
patients in the intervention arm suffered more frequent
complications including renal impairment and more venti-
lation days [25]. Although it remains unclear whether the
PCT protocol could not identify the correct patients in
whom therapy should have been escalated or whether the
intervention was not beneficial per se, therapy escalation
based on PCT concentrations cannot yet be recommended
in the sepsis setting [26]. Importantly, the above-men-
tioned interventional study used daily PCT measurement
to guide decisions concerning antibiotic therapy escalation.
Our data suggest that a longer measurement interval, that
is, 72 hours, may be an effective alternative strategy to
support decision-making.
Interestingly, the presence and speed of CRP decrease
also have been found to correlate with prognosis in ICU
patients with severe pneumonia [6]. Specifically, the ratio
of follow-up CRP measurements to the baseline measure-
ment during the first week of therapy correlated closely
with the individual clinical evolution. It will be interesting
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kinetics in a head-to-head study.
Importantly, there were differences in our two study
populations. The derivation cohort had mostly white
patients with confirmed severe sepsis or septic shock
with higher initial PCT levels and a higher ICU mortality
rate. The validation cohort had a lower overall severity
with patients with a broader spectrum of sepsis or severe
systemic infection and a lower ICU mortality rate. More-
over, the derivation cohort had a substantially greater
proportion of women, and, as a result, an appreciably
higher prevalence of the urinary tract as the primary
locus of sepsis, while the validation cohort was much
more diverse with respect to the primary locus of sepsis.
These discrepancies may partly explain the differences in
performance of 72-hour PCT kinetics, particularly when
looking at the 80% decrease cut-off and in-hospital mor-
tality. Future studies should address whether algorithms
need to be adjusted in lower-severity patients, as is the
case with antibiotic stewardship algorithms when applied
in different clinical settings [21]. Such adjustment also
may be needed when choosing the optimal negative and
positive predictive values of PCT, which should depend
on the outcome prevalence, and thus the expected risk,
of the typical patient in the setting of interest.
Limitations of this work should be noted. As an obser-
vational retrospective analysis with patient inclusion
based on medical records and with patients treated at dif-
ferent types of ICUs, the study may have had a selection
bias. The results, therefore, need additional, prospective
validation in a larger patient population. Our sample was
too small to adjust for multiple confounders or to investi-
gate effect modification by underlying illness or type of
ICU. We restricted our analysis to patients with con-
firmed or likely sepsis who survived at least the first 60
hours of critical care, limiting the generalizability to
other populations. Additionally, we used a different
severity of illness score (APACHE IV or SAPS II) for
adjusting the regression models in each cohort, reflecting
routine institutional choice; use of different scores may
limit comparability between our two cohorts. Also, the
cohorts included different patient populations regarding
their sepsis syndrome, which again limits comparability
and calls for prospective validation in a well-defined
patient cohort. Importantly, in a second step, interven-
tional trials need to be conducted to ultimately character-
ize the impact of PCT monitoring on patient care and
pharmacoeconomics.
Conclusions
This analysis found that PCT kinetics over the first 72
hours of critical care provided prognostic information
about ICU mortality and in-hospital mortality in patients
with confirmed or likely sepsis independent of state-of-
the-art initial clinical severity scores in two US settings,
thereby extending observations of previous European stu-
dies. Further investigation is needed to validate these find-
ings more definitively and to show whether monitoring
PCT will improve patient outcomes and health care
resource use.
Key messages
￿ Close monitoring and repeated risk assessment of
sepsis patients in the ICU is important for decisions
regarding care intensification or early discharge to
the ward.
￿ In this two-center, retrospective derivation-valida-
tion study, the change in PCT levels over the first
72 critical care hours in ICU patients with confirmed
or likely sepsis showed a strong association with
adverse outcome, including in-hospital and ICU
mortality.
￿ The prognostic information derived from PCT
kinetics was independent of initial clinical risk score
(APACHE IV or SAPS II).
￿ A 72-hour PCT decrease >80% had a negative pre-
dictive value of around 90%; conversely, no decrease
or an increase in PCT over 72 hours had a positive
predictive value around 50%.
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